Specifically, within the private equity space, what services/funds do you offer?
Our funds offer investors an opportunity to invest in well managed, selected emerging breakthrough companies with high projected revenue growth in biotech and technology with an upcoming projected liquidity event typically 1-3 years out. We focus on hard to source but well known exceptional growth tech companies.
How does it feel to win this prestigious award?
It feels great and I am thankful to Wealth & Finance International for their recognition and the award and appreciate their support of our industry!
What do you feel is the secret behind your firm’s success?
The secret is nothing new. Finding great companies to invest in. Putting in the hard work to help these companies, surrounding yourself with those smarter than you in your areas of weakness, learning from those smarter than you, being humble and building great relationships that last was instrumental to our firm’s success.
Formulas change, investment strategies change but relationships don’t and neither does having a good heart and great integrity. I also learned that it is important to sell what sells. Just because you have a great investment strategy doesn’t mean people will invest in it.
What is your firm’s mission and what steps do you take to achieve it?
Our firm’s mission is to help eradicate cancer and invest in human progressive endeavours. We can do this by helping and investing into great companies with strong management teams and by working side by side with companies and being an integral part of the management team. Our work at Genprex will continue indefinitely and we believe it will become a major game changer in the cancer biotech industry. We believe mankind is at the beginning of the Great Age of Biotech.
I think Genprex could be a global leader in cancer gene therapy. Dr. Jack Roth, the inventor of Oncoprex is a gene therapy pioneer and leading lung cancer surgeon so supporting him, the officers and the company during this development phase was key to its current success. The potential to save and improve the lives of millions of cancer patients around the world is an honour and a major responsibility at the same time. Please give us an overview of the private equity industry in your region currently. What are the major challenges and opportunities you encounter? The venture capital and private equity markets in Seattle is very vibrant and busy. We have amazing tech and biotech start-ups emerging from Seattle all the time and it is a hub of the tech titans from Amazon, Microsoft, Facebook, Google and so on.
For the most part start-ups are getting funding for great ideas and startups are more focused on the bottom line than they have previously. The ability to scale with technology and the lowering of operating costs due to Amazon Web Services and Azure has helped many tech start-ups control costs and cash burn and helped move into profitability quicker. Talent has never been better as very smart entrepreneurs either graduate or leave established companies looking to fill niche areas in the marketplace and tech scene. Major opportunities that I am focusing on moving forward, in my opinion is biotech and space endeavours.
The Cosmos and the Microcosm present equal challenges and major opportunities. Biotech has a faster ROI but ‘space’ has infinite revenues. I can’t speak glowingly enough about Elon Musk and SpaceX’s mission.
It reminds me of the Vanderbilt’s construction of the railroad system in the 19th century. The railroads created new commerce hubs and major cities thus expanding the GDP of the country and SpaceX is fulfilling the same destiny but for interplanetary commerce, colonisation and ultimately building whole new global sources of GDP. SpaceX is building railroads to the stars and when you map out the potential revenues, one can see that infinite revenues are possible in the longer terms and that growth looks potentially unlimited. This is the first time I have ever used the infinite symbol when describing long term revenue growth. In my opinion, SpaceX could be the first trillion-dollar market cap company, if not the first, one of.
What does the future have in store for your business? Do you have any specific projects or plans you would be willing to share with us?
Genprex will keep me busy for a long time, as will working on my foundation and managing our VC funds. Cancer has been exceptionally difficult to treat due to the thousands of different genetic mutations of cancer. Humans are waging a major molecular biological war. I believe we are on the cusp of major technological breakthroughs in cancer medicine. These innovations will also give us the ability to eradicate most cancers or control them within the next 25 years. Immunotherapy, regenerative medicine, gene therapy, gene editing, stem cell therapies and robotics will all play a role in helping treat the 10,000 diseases that afflict the human body.
We are also planning a documentary on Genprex, biotech start-ups and on the cancer biotech industry later in 2017, chronicling the Genprex story, our journey and to support the fine men and women at our hospitals and research centres, trying to find the cure and to ultimately destroy or control cancer, once and for all.
Do you have anything you would like to add?
Yes, look for Genprex’s (GPRX) IPO in late Q1 on Nasdaq, invest in us if you believe in our mission and company and to follow our story.
Name: Viet Ly
Web Address: www.inceptionfunds.com; www.genprex.com
Address: 5400 Carillon Point Road Building 5000, 4th Floor Kirkland, WA 98033
Telephone: 1 855-22-FUNDS